A phase I study of Lapatinib (GW572016) and topotecan in patients with solid tumors.

被引：0
|
作者：
Erlichman, C
Adjei, AA
Joy, ME
Rubin, SD
Friedman, RA
Ames, MM
Reid, JM
Molina, JR
机构：
[1] Mayo Clin, Rochester, MN USA
[2] GlaxoSmithKline Oncol, Res Triangle Pk, NC USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8994S / 8994S
页数：1
相关论文
共 50 条
  • [1] A phase I study of lapatinib (GW572016) and topotecan in patients with solid tumors
    Molina, JRM
    Adjei, AA
    Erlichman, C
    Mandrekar, S
    Joy, ME
    Rubin, SD
    Reid, J
    ANNALS OF ONCOLOGY, 2006, 17 : 49 - 49
  • [2] A phase I study of GW572016 in patients with solid tumors
    Minami, H
    Nakagawa, K
    Kawada, K
    Mukai, H
    Tahara, M
    Kurata, T
    Uejima, H
    Nogami, T
    Sasaki, Y
    Fukuoka, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 207S - 207S
  • [3] Phase I study of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q.
    Rowinsky, E.
    Goldstein, L.
    Cianfrocca, M.
    Murray, N.
    Gale, M.
    Ho, P. T.
    Loftiss, J. I.
    Paul, E.
    Pandite, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 119
  • [4] A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.
    Pandite, L
    Burris, HA
    Jones, S
    Wilding, G
    Taylor, C
    Versola, MJ
    Smith, DA
    Stead, A
    Koch, KM
    Spector, NL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 238S - 238S
  • [5] The Discovery of Lapatinib (GW572016)
    Rusnak, David
    Gilmer, Tona M.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2019 - 2019
  • [6] Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors
    Siegel-Lakhai, Wandena S.
    Beijnen, Jos H.
    Vervenne, Walter L.
    Boot, Henk
    Keessen, Marianne
    Versola, Melissa
    Koch, Kevin M.
    Smith, Deborah A.
    Pandite, Lini
    Richel, Dirk J.
    Schellens, Jan H. M.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4495 - 4502
  • [7] A phase I study of lapatinib and topotecan in patients with solid tumors
    Molina, J. R.
    Erlichman, C.
    Kaufmann, S.
    Adjei, A.
    Rubin, S.
    Friedman, R.
    Reid, J.
    Qin, R.
    Felten, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer.
    Iwata, H.
    Toi, M.
    Fujiwara, Y.
    Ito, Y.
    Fujii, H.
    Nakamura, S.
    Aogi, K.
    Zaks, T.
    Sasaki, Y.
    Takashima, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [9] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q
    Cianfrocca, ME
    Murray, N
    Oslund, M
    Nelson, LM
    Rowinsky, E
    Schwartz, G
    Goldstein, LJ
    Loftiss, JI
    Paul, E
    Koch, KM
    Pandite, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S235 - S235
  • [10] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab
    Storniolo, AM
    Burris, HA
    Overmoyer, B
    Silverman, P
    Pegram, MD
    Jones, SF
    Peacock, NW
    Loftiss, J
    Koch, KM
    Paul, E
    Ho, PTC
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S64 - S64
12345